Chemical Research in Chinese Universities ›› 2026, Vol. 42 ›› Issue (4): 1260-1268.doi: 10.1007/s40242-026-6114-0

• Research Articles • Previous Articles     Next Articles

Multiplexed Lateral Flow Immunoassay with Catalytic Signal Amplification for Simultaneous Quantitative Detection of Five Cardiac Biomarkers in Acute Chest Pain Triage

SONG Dan1,2, WANG Haodong3, SUN Xudong1,2, WU Fuchao1,2, TONG Qian3, WANG Zhen-Xin1,2   

  1. 1. Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, P. R. China;
    2. School of Applied Chemical Engineering, University of Science and Technology of China, Hefei 230026, P. R. China;
    3. Department of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun 130021, P. R. China
  • Received:2026-05-20 Revised:2026-06-17 Online:2026-08-01 Published:2026-07-28
  • Contact: WANG Zhen-Xin,E-mail:wangzx@ciac.ac.cn;WANG Haodong,E-mail:haodongwang@jlu.edu.cn E-mail:wangzx@ciac.ac.cn;haodongwang@jlu.edu.cn
  • Supported by:
    This work was supported by the Program of Jilin Provincial Science and Technology Department, China (Nos. 20230204074YY, YDZJ202601ZYTS456), the Doctor Excellence Program (DEP) at the First Hospital of Jilin University, China (No. JDYY-DEP-2024046), and the 16th Hospital Youth Development Fund of the First Hospital of Jilin University, China (No. JDYY16202510).

Abstract: Acute chest pain is a life-threatening clinical emergency requiring rapid differentiation of acute myocardial infarction (AMI), acute aortic dissection (AAD), and pulmonary embolism (PE). Conventional diagnostics are limited by bulky equipment, delayed processing, and insufficient specificity. We developed a portable dual-readout lateral flow immunoassay (Multi-AuPd@FexOy-LFIA) for one-step identification of high-risk acute chest pain etiologies, enabling simultaneous determination of five key biomarkers: soluble suppression of tumorigenicity 2 (sST2), D-Dimer, cardiac troponin I (cTnI), myoglobin (MYO), and C-reactive protein (CRP). A 3D-printed smartphone cradle and APP enabled automated signal readout. The multi-AuPd@FexOy-LFIA exhibits low limits of detection (LODs) of 0.036 ng/mL (sST2), 0.008 μg/mL (D-Dimer), 0.017 ng/mL (cTnI), 0.732 ng/mL (MYO), and 3.327 μg/mL (CRP). Based on the analysis of the concentrations of the five biomarkers in 137 clinical plasma samples, least absolute shrinkage and selection operator (LASSO) machine learning establishes a four-category classification model, with areas under curves (AUCs) reaching 0.99―1.00 for distinguishing healthy donors, AMI, AAD, and PE. The established machine learning diagnostic algorithm is further integrated into the App, enabling Multi-AuPd@FexOy-LFIA to achieve quantitative detection and early differential diagnosis of acute chest pain.

Key words: Lateral flow immunoassay, Nanozyme, Acute chest pain, Multiplexed biomarker detection, Machine learning, Point-of-care testing